Latest News | Sun Pharma Commences Phase 2 Clinical Trial for Psoriasis Drug
Get latest articles and stories on Latest News at LatestLY. Sun Pharma on Monday said it has initiated Phase 2 clinical trial for a product being developed to treat patients with moderate to severe plaque psoriasis.
New Delhi, Jan 4 (PTI) Sun Pharma on Monday said it has initiated Phase 2 clinical trial for a product being developed to treat patients with moderate to severe plaque psoriasis.
The Phase 2 study is a randomised, double-blind, placebo-controlled study to assess the efficacy and safety of SCD-044 (novel molecule) in the treatment of moderate to severe plaque psoriasis, Sun Pharmaceutical Industries said in a statement.
The study will enrol around 240 subjects and topline results are expected in 2022, it added.
SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis, are also expected to be initiated soon, the Mumbai-based drug major said.
In May last year, Sun Pharma entered into a worldwide in-licensing agreement with Sun Pharma Advanced Research Company Ltd (SPARC) for the development and commercialisation of SCD-044.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)